Traders News Source Senior Editor Mark Roberts Interviews Denis D Corin, CEO and Chairman Q BioMed Inc.

Traders News Source Senior Editor Mark Roberts Interviews Denis D Corin, CEO and Chairman Q BioMed Inc. (OTCQB: QBIO) a biotech acceleration and commercial stage company focused on licensing and acquiring undervalued biomedical assets in the healthcare sector.

Denis D Corin
CEO and Chairman
Mr. Denis D. Corin is Chief Executive Officer and Chairman of the Board. Mr. Corin is an experienced public company executive and management consultant. He has worked almost exclusively in the biomedical field for over 13 years from large pharma and diagnostic companies to small innovative biotech. He has served in various senior executive roles and has been instrumental in building and restructuring businesses. Mr. Corin has raised millions of dollars in development capital to advance businesses. Mr. Corin also served as a Management Consultant to the executives and board of TapImmune Inc. (NASD:TPIV), a clinical stage immune -oncology company through 2014. He holds a Bachelors Degree majoring in both Economics and Marketing & Advertising Management from the University of Natal, South Africa.

Full Interview

Could you give us a brief overview and future vision for your company?

We started Q BioMed in 2015 with the vision of finding high value assets that had with huge potential that we could accelerate to a point of real value creation by providing both the funds and human capital to advance to a monetization event. We also wanted to have at least one asset that was close to commercial that we could commercialize and start to generate revenues to de-risk the portfolio.

Over the last 7 years we have done just that. We have a commercial asset we are now monetizing through commercial sales and have the option to sell or grow. We have several other high value assets that address markets in excess of $170 Million that are all approaching monetization events this year. So, to answer your question, I see us creating significant value through the monetization of the assets we have developed so far. We have several opportunities to do so over the next 12 months and many of them will require much more capital investment from us.

Strontium89 sales revenue has increased dramatically. Can you discuss the total addressable market for that product?

Bone pain is one of the most common types of pain in cancer patients [1]. Approximately 60–84% of patients with advanced cancer are estimated to experience varying degrees of bone pain [2]. This condition affects millions of patients worldwide, with nearly 450,000 patients annually in the USA alone [3]. Our drug has a very broad label making it available to not only breast and prostate, but to ALL cancers that metastasize to bone. That’s a huge number of potential patients in the US and much larger if taken globally. It is estimated there are over 10 million patients currently suffering from bone pain cased by this terrible disease.

You have discussed seeking a partnership to bring Uttroside-B to clinical trials. Could you be specific as to that potential partnership search?

Yes – we have had a few discussions with interested parties, but I am not in a position to elaborate just yet. The recent data we announced showing that in animal studies our drug looks to be not only safe but more effective than the current offering is an additional validation of the work done to date and we are excited to see where this leads in the near future.

Beyond Uttroside-B, QBIO has several other products in the preclinical stage, which of those products do you expect will develop the fastest?

We have an exclusive license and development agreement with Mannin Research through which we have a 50% royalty on their entire portfolio. Mannin is quickly approaching a clinical program for acute respiratory distress syndrome (ARDS) a condition that affected millions of COVID patients and those with severe influenzas, pneumonia, and sepsis. That same pre-clinical package may also be used for clinical approvals in the other indications we have been working on, namely, glaucoma and diabetic kidney disease. Together the addressable market for this portfolio is well over $150 Billion. We expect the first clinical trial to be completed in the next 8 months. A positive read out from that could be a very significant value catalyst.

Could you discuss the QBIO portfolio of patents and patents pending?

We have several patents through our licensing partners. While the patents ultimately are owned by the universities, institutions, or inventors, we have global exclusive licenses on all of these programs.

What is the current cash position at QBIO? And does the company have solutions it’s considering for funding operations though FYE 2022?

Current market conditions have made raising capital challenging. Biotech has been particularly hard hit. We continue to raise small amounts of cash along with the revenues to move the business forward. We are currently evaluating several strategic opportunities to make the move to Nasdaq and a better availability of longer-term capital.

QBIO has a viable oncology product experiencing rapidly growing revenues, yet the company’s market value has dropped considerably. Can you address that paradox and tell our readers why QBIO is a sound investment in the near term?

Last year we were poised for a very large investment partnership in the amount of $30M that would have set us up for significant advancement and up listing. Unfortunately, the funders family office reneged and collapsed on the day of our closing. That lead to us this point where we have not completed our uplifting and larger funding, however, the fundamentals are actually far better than they were at that time. In fact, they are stronger now than ever. We have a fully approved product with a complete marketing and branding package ready to go, fully reimbursed by Medicaid and Medicare, a federal supply contract to sell into the VA, DoD etc. and we are starting to generate revenues, without a sales force in place. We have advanced Uttroside B to a point where its ready to take to the clinic as a potential blockbuster drug. We have a series of potential drug products in development with Mannin that are about to get validated and commercialize or monetize, and that entire program is now heavily funded by non-dilutive capital from the Canadian and German governments. We expect to convert our royalty in Mannin into equity which will immediately add several million dollars to our balance sheet where currently the royalty has no asset value. Mannin prospect for its own value catalyst is excellent and their proforma revenues could be quite significant over the next 24 months. All in all, the current valuation in my opinion is significantly below what the asset value of the company is, and this should translate to a good return as we hit some of the milestones discussed. As always there is risk in biotech, but with risk comes reward.

Thank you,

The Traders News Team


***The owners and operators of this website have NOT been compensated in any way for conducting or distributing this interview. Furthermore, we do not hold any form of equity in the publicly traded company/companies mentioned above***


Privacy Policy and Disclaimer
Your Consent
By using our site, you consent to our online privacy policy and disclaimer.
Do we disclose any information to outside parties?
We do not sell your information to anyone.
What information do we collect?
We collect information from you when you subscribe to our newsletter or fill out a form on one of our social platforms. This includes your email address and or mobile phone number.
When registering on our site, as appropriate, you may be asked to enter your: e-mail address and or mobile number.
What do we use your information for?
When we collect your email or mobile number it is used for one purpose to send you the information you requested about small cap stocks. Please read our disclaimer carefully before viewing our emails.
Your information, whether public or private, will not be sold, exchanged, transferred, or given to any other company for any reason whatsoever, other than for the express purpose of delivering the information on small cap stocks that you requested.
We send periodic emails.
The email address you provide may be used to send you information, the small cap stock reports you requested, respond to inquiries, and/or other requests or questions.
How do we protect your information?
We implement a variety of security measures to maintain the safety of your personal information when you enter, submit, your email address. We use secure third parties to send email and sms messages to you.
Because we value your privacy we have taken the necessary precautions to be in compliance with the California Online Privacy Protection Act.
Online Privacy Policy Policy
This online privacy policy applies to information collected through our website and social media platforms.
Contacting Us
If there are any questions regarding this privacy policy or disclaimer you may contact us using the information below.
Traders News Source is a wholly owned subsidiary of Traders News Source LLC, herein referred to as TNS LLC.
Our reports/releases are a commercial advertisement and are for general information purposes ONLY. We are engaged in the business of marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our services, joining our site or our email/blog list as well as any social networking platforms we may use.
Please Note: TNS LLC and its employees are not a registered investment advisor, Broker Dealer or a member of any association for other research providers in any jurisdiction whatsoever.
Release of Liability: Through use of this website viewing or using you agree to hold TNS LLC, its operators owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. TNS LLC encourages readers and investors to supplement the information in these reports with independent research and other professional advice.
All information on featured companies is provided by the companies profiled, or is available from public sources and TNS LLC makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. None of the materials or advertisements herein constitute offers or solicitations to purchase or sell securities of the companies profiled herein and any decision to invest in any such company or other financial decisions should not be made based upon the information provide herein. Instead TNS LLC strongly urges you conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. Readers are advised to review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D.
TNS LLC is compliant with the Can Spam Act of 2003. TNS LLC does not offer such advice or analysis, and TNS LLC further urges you to consult your own independent tax, business, financial and investment advisors. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investors investment may be lost or impaired due to the speculative nature of the companies profiled.
The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results.
In preparing this publication, TNS LLC has relied upon information supplied by its customers, publicly available information and press releases which it believes to be reliable; however, such reliability cannot be guaranteed. Investors should not rely on the information contained in this website. Rather, investors should use the information contained in this website as a starting point for doing additional independent research on the featured companies. The advertisements in this website are believed to be reliable, however, TNS LLC and its owners, affiliates, subsidiaries, officers, directors, representatives and agents disclaim any liability as to the completeness or accuracy of the information contained in any advertisement and for any omissions of materials facts from such advertisement.
TNS LLC is not responsible for any claims made by the companies advertised herein, nor is TNS LLC responsible for any other promotional firm, its program or its structure.
TNS LLC is not affiliated with any exchange, electronic quotation system, the Securities Exchange Commission or FINRA. TNS LLC is not a Broker/Dealer and does not engage in high frequency trading.